Pazopanib for early lung cancer
September 15th, 2008
An innovative trial has shown pazopanib, a new oral angiogenesis inhibitor, to demonstrate interesting activity in difficult to treat non-small-cell lung cancer. 30 out of 35 patients treated with preoperative pazopanib for a minimum of two weeks saw their tumour size shrink by up to 85% in the phase II trial announced at the 33rd European Society for Medical Oncology meerting in Stockholm.